Last Updated : April 10, 2024
Details
Generic Name:
venetoclax
Project Status:
Pending
Therapeutic Area:
Chronic lymphocytic leukemia (CLL).
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
Venclexta
Project Line:
Reimbursement Review
Project Number:
PC0362-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
AbbVie requests reimbursement of venetoclax, in combination with obinutuzumab for the subgroup of previously untreated CLL patients considered potentially fludarabine-eligible, who were not included in the reimbursement request or recommendation criteria in the previous CADTH review (PC0212-000). Note that based on this request, the reimbursement criteria for venetoclax in combination with obinutuzumab would be expanded for the previously untreated CLL patients, irrespective of age or eligibility for fludarabine treatment (i.e., aligned with the Health Canada indication).
Submission Type:
Reassessment
Fee Schedule:
Pending
Indications:
Venclexta (venetoclax), in combination with obinutuzumab, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : April 10, 2024